UNSPSC 51422414: Halcinonide

This classification denotes a therapeutic glucocorticoid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SI86V6QNEG. European Medicines Agency schedules Halcinonide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07994MIG. Halcinonide generally arises in the molecular formula C24H32CLFO5.

UNSPSC 51422414 Halcinonide is a Commodity code that nominally identifies a specific topical corticosteroid pharmaceutical, but recent state and local procurement activity under this code shows a marked mismatch: the two recent opportunities solicited Naloxone (an opioid antagonist for emergency overdose response) and direct-to-manufacturer prescription program capabilities, neither of which align with the halcinonide product scope. The code appears to be misapplied by issuing agencies, or the taxonomy entry does not reflect the actual pharmaceutical procurement work being conducted. State and local health and human services departments are the primary issuing bodies, ranging from county-level community health programs to statewide HHS commissions managing pharmacy benefit strategy and emergency opioid response initiatives.

Geographic activity centers on Florida and Texas. Seminole County, Florida released an Invitation for Bid (IFB 60459723LAS) on June 30, 2026 for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries, with a response deadline of July 26, 2023 at 2:00 pm; the contract runs two years with a one-year renewal option and includes FEMA funding with attendant federal compliance requirements. The Texas Health and Human Services Commission issued a Request for Information (RFI HHS0017013) on April 3, 2026 to gather vendor capabilities on direct-to-manufacturer pharmacy prescription programs outside traditional pharmacy benefit manager channels. Bidders should note that recent halcinonide-coded opportunities do not reflect pharmaceutical products matching the code name and instead signal either data quality issues in state and local taxonomy application or a broader shift in how health agencies classify drug procurement in their systems.